OMDA Omada Health, Inc.

Nasdaq www.omadahealth.com


$ 24.51 $ 0.52 (2.17 %)    

Tuesday, 14-Oct-2025 15:59:55 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 24.52
$ 23.66
$ 23.95 x 5
$ 24.98 x 100
$ 22.76 - $ 24.95
$ 14.14 - $ 28.40
177,273
na
538.73M
nm
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that sho...

Core News & Articles

Baird analyst Vikram Kesavabhotla initiates coverage on Omada Health (NASDAQ:OMDA) with a Neutral rating and announces Price...

Core News & Articles

Canaccord Genuity analyst Richard Close maintains Omada Health (NASDAQ:OMDA) with a Buy and raises the price target from $27...

Core News & Articles

Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:OMDA) with a Overweight and raises the price target from $21 to ...

Core News & Articles

Needham analyst Ryan MacDonald maintains Omada Health (NASDAQ:OMDA) with a Buy and raises the price target from $23 to $24.

Core News & Articles

Financial OutlookFor the year ending December 31, 2025, Omada expects:Revenue in the range of $235 million to $241 millionAdjus...

Core News & Articles

Omada Health (NASDAQ:OMDA) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.14...

Core News & Articles

Evercore ISI Group maintains Omada Health (NASDAQ:OMDA) with a Outperform and raises the price target from $21 to $23.

 omada-health-analysts-say-buy--while-its-still-below-ipo-price

Omada Health is poised to generate over 35% growth while approaching adjusted EBITDA breakeven, Needham analysts say.

Core News & Articles

JP Morgan analyst Destiny Jackson initiates coverage on Omada Health (NASDAQ:OMDA) with a Overweight rating and announces Pr...

Core News & Articles

Morgan Stanley analyst Craig Hettenbach initiates coverage on Omada Health (NASDAQ:OMDA) with a Overweight rating and announ...

Core News & Articles

Goldman Sachs analyst David Roman initiates coverage on Omada Health (NASDAQ:OMDA) with a Buy rating and announces Price Tar...

Core News & Articles

Barclays analyst Saket Kalia initiates coverage on Omada Health (NASDAQ:OMDA) with a Overweight rating and announces Price T...

Core News & Articles

Needham analyst Ryan MacDonald initiates coverage on Omada Health (NASDAQ:OMDA) with a Buy rating and announces Price Target...

Core News & Articles

Canaccord Genuity analyst Richard Close initiates coverage on Omada Health (NASDAQ:OMDA) with a Buy rating and announces Pri...

 hinge-healths-tech-is-primed-to-capture-americas-untapped-msk-pain-market-analyst

Analysts initiate coverage of Hinge Health with Buy ratings, citing strong tech, recurring revenue, and a growing $18.5 billion...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION